Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Revisiting the relevance of sidedness in colonic tumor molecular profiling.

Ashok K. Vaid, Aditya Sarin, Muzammil Shaikh et al. Jun 01, 2025 pp. 3531-3531 10.1200/jco.2025.43.16_suppl.3531

3531 Background: Colorectal cancer (CRC) is a heterogeneous disease with distinct molecular and clinical differences between right- and left-sided tumors....

Results of a program addressing multi-level barriers to completion of hereditary cancer genetic testing (GT) among underserved and minority individuals in Texas.

Darya Aleksandrovna Kizub, Kelly Meza, Ana Ruiz Cuevas et al. Jun 01, 2025 pp. 10593-10593 10.1200/jco.2025.43.16_suppl.10593

10593 Background: 5-10% of breast and colorectal cancers are hereditary, but uptake of GT among eligible individuals remains low. Our previous study showe...

Receipt of guideline concordant oncologic care between older HIV-positive and older HIV-negative patients with cancer.

Uma Markan, David Riedel, Habib Omari et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23067

e23067 Background: Given the success of anti-retroviral therapy (ART), the population of people living with HIV (PLWH) is aging. More than half of PLWH ar...

Long-term outcomes in Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy.

Karan Chohan, Lorenzo Gensini, Sherif Seif et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19082

e19082 Background: BTKis have revolutionized the care of Waldenström macroglobulinemia (WM); however, treatment duration can be limited by adverse events...

Sex, racial and ethnic disparities in early-onset versus average-onset gastrointestinal cancers: A population-based analysis.

Sara F. Haddad, Anthony Kerbage, R. Blake Buchalter et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15683

e15683 Background: Early-onset (EO) gastrointestinal (GI) cancers (diagnosed at 18–49 years) are increasingly recognized as distinct from average-onset (A...

Circulating tumor cells as prognostic biomarkers in advanced gastric cancer treated with CDC25B phosphatase inhibitors.

Francisco Cezar Aquino de Moraes, Danielle Queiroz Calcagno, Emanuele Rocha da Silva et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16050

e16050 Background: Targeted therapies, such as the CDC25B inhibitor menadione, have shown promise in treating gastric cancer (GC). Circulating tumor cells...

Evaluation of a novel method for rapid collection of microgram amounts of cell free DNA.

Floyd Taub, Lindsey Ray, Charles Preston Neff et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15048

e15048 Background: Cell free DNA (cfDNA) and cell free cancer DNA (ctDNA) have become common place for monitoring the progression of mutations, the presen...

Effect of chemotherapy treatment on immunotherapy efficacy in colorectal cancer (CRC) patients with high microsatellite instability (MSI-H) and/or tumor mutational burden (TMB-H).

Vi Kien Chiu, Adele Lerolle-Chiu Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14561

e14561 Background: Immune checkpoint inhibitors (ICI) are more effective than chemotherapy (CT) in treating MSI-H CRC in the metastatic and neoadjuvant se...

Sequencing-guided chemotherapy optimization using real-time evaluation in newly diagnosed DLBCL with circulating tumor DNA: SHORTEN-ctDNA (NCT06693830).

Hua-Jay Jeffery Cherng, Stephanie Meek, Cheng-Shiun Leu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps7095

TPS7095 Background: Circulating tumor DNA (ctDNA) is a clinically valid tool for detection of measurable residual disease (MRD) in patients with diffuse l...

Survival impact of Neo <i>RAS</i> wild-type metastatic colorectal cancer: A SCRUM-Japan GOZILA substudy.

Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura et al. Jun 01, 2025 pp. 3530-3530 10.1200/jco.2025.43.16_suppl.3530

3530 Background: The “Neo RAS ’’ phenomenon refers to KRAS or NRAS mutant (MT) met...

Safety and efficacy of HLA-G–targeted CAR T cells (IVS-3001) in patients with advanced HLA-G–positive solid tumors: Clinical trial in progress.

Samer Ali Srour, Nizar M. Tannir, Amir A. Jazaeri et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps2679

TPS2679 Background: Immunotherapies have transformed cancer treatment, yet only a small proportion of patients experiences durable responses. IVS-3001 is...

Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC).

Andrew Scott Brohl, Melissa Amber Burgess, Gino Kim In et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps9603

TPS9603 Background: CPIs have revolutionized the treatment of a wide variety of cancers. Despite their success, the majority of cancers do not respond pri...

Phase 1 expansion study of FF-10832 (liposomal gemcitabine) antitumor activity in patients with advanced biliary carcinomas.

Gerald Steven Falchook, Erkut H. Borazanci, Bruce Shih-Li Lin et al. Jun 01, 2025 pp. 4092-4092 10.1200/jco.2025.43.16_suppl.4092

4092 Background: FF-10832 has demonstrated improved pre-clinical anti-tumor activity compared to gemcitabine (GEM). Associated factors may include its pro...

Preliminary results from a phase IIa trial of APG-157 in oral cavity and oropharyngeal dysplasia.

Luke van Leeuwen, Garrett Forman, Janice Jing Huang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18119

e18119 Background: Oral and oropharyngeal squamous cell carcinoma affects over 678,900 people annually and is often preceded by potentially malignant lesi...

Estimation of population attributable fractions based on integrated global cancer incidence data, 1990-2021.

Yongjie Xu, Shiyuan Tong, Changfa Xia et al. Jun 01, 2025 pp. 10536-10536 10.1200/jco.2025.43.16_suppl.10536

10536 Background: The global cancer burden is increasing, yet emerging risk factors for cancer incidence have not been comprehensively summarized in terms...

Results from phase 1 study of mycophenolate mofetil with chemoradiation in newly diagnosed glioblastoma to target de-novo purine metabolism to overcome treatment resistance.

Yoshie Umemura, Nathan Clarke, Wajd Al-Holou et al. Jun 01, 2025 pp. 2015-2015 10.1200/jco.2025.43.16_suppl.2015

2015 Background: Mycophenolate mofetil (MMF) inhibits IMPDH and disrupts de novo purine synthesis which is preferred by glioblasto...

DeepSeal: Empowering clinical researchers to analyze clinicogenomic data with an intuitive chat-based interface.

Gaurav Sharma, Shawn Baker, Guillaume Marcais et al. Jun 01, 2025 pp. 1562-1562 10.1200/jco.2025.43.16_suppl.1562

1562 Background: Traditional clinicogenomic analysis workflows in oncology require substantial bioinformatics expertise and custom coding, creating a bott...

PlP-powered exosomal therapeutics: Redefining immune activation in therapy-resistant tumor microenvironment.

Francisco Krakowiak, Ramon Gutierrez-Sandoval, Francisco Gutierrez-Castro et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14512

e14512 Background: Tumor immunosuppression is a major obstacle in developing effective oncological therapies, particularly in pediatric, adolescent, young...

Burden of pediatric CNS malignancies across 204 countries from 1990 to 2021.

Muzamil Khan, Waseem Nabi, Nouman Aziz et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14032

e14032 Background: Central nervous system (CNS) tumors are a leading cause of cancer-related morbidity and mortality among children. Understanding the glo...

Multiple immune related adverse events among patients with melanoma: Patterns and risk factors.

John Hunting, Chance Bloomer, Sarah Price et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14651

e14651 Background: CheckMate-067 recently trial demonstrated the significant long-term survival benefit of combining ipilimumab and nivolumab versus singl...

Phase II study evaluating 68Ga-FAPI PET uptake heterogeneity as a predictor of T-DXd treatment response in HER2-positive breast cancer brain metastases.

Biyun Wang, Yannan Zhao, Zhongyi Yang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps1122

TPS1122 Background: Breast cancer is a leading cause of metastasis to the central nervous system (CNS). Approximately 30% of patients with HER2-positive b...

Treatment outcomes and patients’ characteristics of malignant phyllodes breast neoplasms: A tertiary care center experience.

Basil Jalamneh, Moath Albliwi, Wahid Aloweiwi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13159

e13159 Background: Phyllodes tumors (PTs) are rare breast neoplasms (&lt;1% of breast tumors), classified as benign, borderline, or malignant. Surgical ex...

Worldwide experience of chronic active EBV infection: Retrospective cohort study.

Xinran Wang, Hui Luo, Ning An et al. Jun 01, 2025 pp. 7016-7016 10.1200/jco.2025.43.16_suppl.7016

7016 Background: Chronic active Epstein-Barr virus disease (CAEBV) is a rare, life-threatening disorder characterized by systemic inflammation and clonal...

Molecular profiling and prognosis of spindle cell/sclerosing rhabdomyosarcoma: A report from the Chinese PPOG trial.

Suying Lu, Junting Huang, Feifei Sun et al. Jun 01, 2025 pp. 11566-11566 10.1200/jco.2025.43.16_suppl.11566

11566 Background: Spindle cell/sclerosing rhabdomyosarcomas (SSRMS) is a rare variant of rhabdomyosarcoma, recognized as a distinct pathological entity in...

Effect of early integrated neuropsychological care in patients with brain metastases: A phase 2 randomized controlled trial (ATHENA trial).

Haley Kopp Perlow, Erica L. Dawson, Khaled Dibs et al. Jun 01, 2025 pp. 2031-2031 10.1200/jco.2025.43.16_suppl.2031

2031 Background: Advancements in radiotherapy delivery through both hippocampal sparing whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page